Ohkusa T, Takashimizu I, Fujiki K, Suzuki S, Shimoi K, Horiuchi T, Sakurazawa T, Ariake K, Ishii K, Kumagai J, Tanizawa T
Tokyo Medical and Dental University School of Medicine, Japan.
Ann Intern Med. 1998 Nov 1;129(9):712-5. doi: 10.7326/0003-4819-129-9-199811010-00006.
Helicobacter pylori infection is common in patients with hyperplastic gastric polyps.
To study the effect of eradication of H. pylori on the clinical course of patients with hyperplastic gastric polyps.
Single-blind, randomized, controlled trial.
University-based gastroenterology outpatient clinic.
35 patients with H. pylori infection and hyperplastic gastric polyps at least 3 mm in diameter.
Patients were randomly assigned to a treatment group (n = 17), which received a proton-pump inhibitor (omeprazole or lansoprazole), amoxicillin, and either clarithromycin or ecabet sodium, or to a control group (n = 18), which received no treatment.
Patients underwent endoscopy before enrollment and 12 to 15 months after the end of treatment. Serum gastrin levels and titers of IgG to H. pylori were measured.
In the treatment group, the polyps had disappeared by 3 to 15 months (average, 7.1 +/- 1.2 months) after the end of treatment in 12 of all 17 patients (71%) and in 12 of the 15 patients (80%) in whom H. pylori was eradicated. However, 12 to 15 months after the start of the study, no change in polyps or H. pylori status was seen in any controls (P < 0.001). Histologic findings of inflammation and activity, serum gastrin levels, and titers of IgG to H. pylori showed significant regression in the treatment group compared with the control group (P < 0.01).
Most hyperplastic polyps disappeared after eradication of H. pylori. Thus, eradication should be attempted before endoscopic removal is done in patients with hyperplastic gastric polyps and H. pylori infection.
幽门螺杆菌感染在增生性胃息肉患者中很常见。
研究根除幽门螺杆菌对增生性胃息肉患者临床病程的影响。
单盲、随机、对照试验。
大学附属医院胃肠病门诊。
35例幽门螺杆菌感染且有直径至少3毫米增生性胃息肉的患者。
患者被随机分为治疗组(n = 17),接受质子泵抑制剂(奥美拉唑或兰索拉唑)、阿莫西林以及克拉霉素或依卡倍特钠治疗;或对照组(n = 18),不接受治疗。
患者在入组前以及治疗结束后12至15个月接受内镜检查。检测血清胃泌素水平以及幽门螺杆菌IgG抗体滴度。
治疗组中,17例患者中的12例(71%)在治疗结束后3至15个月(平均7.1±1.2个月)息肉消失,在根除幽门螺杆菌的15例患者中的12例(80%)息肉消失。然而,在研究开始12至15个月后,所有对照组患者的息肉及幽门螺杆菌状态均无变化(P < 0.001)。与对照组相比,治疗组的炎症和活动度的组织学表现、血清胃泌素水平以及幽门螺杆菌IgG抗体滴度均显著改善(P < 0.01)。
根除幽门螺杆菌后,大多数增生性息肉消失。因此,对于增生性胃息肉合并幽门螺杆菌感染的患者,在进行内镜切除之前应尝试根除幽门螺杆菌。